Trial report in Cancer prevention research (Philadelphia, Pa.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01298999 (Randomized Placebo-Controlled Trial of YF476, a Gastrin Receptor Antagonist, in Barrett's Esophagus), which is not on this map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors at 4 institutions in 2 countries.
Julian A AbramsDepartment of Medicine, Columbia University Irving Medical Center, New York, New York. ja660@cumc.columbia.edu.
Armando Del PortilloDepartment of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, New York.ORCID 0000-0002-8507-8450
Caitlin HillsDepartment of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, New York.ORCID 0000-0001-5024-5231
Griselda CompresDepartment of Medicine, Columbia University Irving Medical Center, New York, New York.
Richard A FriedmanHerbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York.
Bin ChengDepartment of Biostatistics, Mailman School of Public Health, Columbia University, New York, New York.
John PonerosDepartment of Medicine, Columbia University Irving Medical Center, New York, New York.
Charles J LightdaleDepartment of Medicine, Columbia University Irving Medical Center, New York, New York.ORCID 0000-0002-3320-2923
Rachel De La RueMRC Cancer Unit, Hutchison-MRC Research Centre, University of Cambridge, Cambridge, United Kingdom.
Massimiliano di PietroMRC Cancer Unit, Hutchison-MRC Research Centre, University of Cambridge, Cambridge, United Kingdom.
Rebecca C FitzgeraldMRC Cancer Unit, Hutchison-MRC Research Centre, University of Cambridge, Cambridge, United Kingdom.
Antonia SepulvedaDepartment of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, New York.
Timothy C WangDepartment of Medicine, Columbia University Irving Medical Center, New York, New York.ORCID 0000-0001-5730-3019
Columbia University Irving Medical Center · USHutchison/MRC Research Centre · GBGeorge Washington University · USNew York University · US
Funding
Tumor Biology and Microenvironment ProgramP30CA013696 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Katherine D Crew · 1985 to 2026
$115.3M
Weight loss-induced Microbiome and Adipokine Changes in Barrett's EsophagusU54CA163004 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ABRAMS, JULIAN, RUSTGI, ANIL K · 2011 to 2022
$12.5M
Gastrin Regulation of Gastric Antral Stem and Corpus Progenitor CellsR01DK128195 · NIDDK · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI WANG, TIMOTHY CRAGIN · 2021 to 2024
$2.0M
Randomized Placebo-Controlled Trial of a Gastrin Receptor Antagonist in Barretts EsophagusR03CA186218 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ABRAMS, JULIAN · 2015 to 2016
$162k
Medical Research Council RG84369NCI NIH HHS P30 CA013696NCI NIH HHS R03 CA186218NCI NIH HHS U54 CA163004NIDDK NIH HHS R01 DK128195
6 · The paper itself
Abstract
Hypergastrinemia has been associated with high-grade dysplasia and adenocarcinoma in patients with Barrett's esophagus, and experimental studies suggest proinflammatory and proneoplastic effects of gastrin on Barrett's esophagus. This is of potential concern, as patients with Barrett's esophagus are treated with medications that suppress gastric acid production, resulting in increased physiologic levels of gastrin. We aimed to determine whether treatment with the novel gastrin/CCK
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.